Please login to the form below

Not currently logged in

Medicus International rebrands as Discovery London

Med comms agency is also promoted to European hub for Publicis' Discovery network
Barbara Joly, Discovery London, Publicis

Publicis has rebranded its London-based medical communications agency Medicus International, bringing it within the group's global Discovery brand.

The agency becomes Discovery London and will act as the European hub for Publicis' Discovery network, standing alongside other hubs in the US and China.

Discovery London will be led by general manager Barbara Joly (pictured above), who said the agency's integration within the Discovery network would see it move from a niche offering being “the pan-European arm of a global network”.

As such it will be aligned with a global network of more than 500 Discovery employees that operate within 10 countries for clients such as AstraZeneca, BMS, Novartis, Pfizer and Sanofi.

Publicis Healthcare Communications' global group president Sam Welch told PMLiVE that bringing Medicus within the Discovery fold would allow a greater degree of seamless integration of its global service offering.

“Discovery is our strongest med comms brand worldwide, so the move to make Medicus International part of that was really done to align the brand on a globally basis.

“For us, it's a fantastic opportunity. We are investing very, very heavily in London and we expect that at some point in the not too distant future [Discovery] London and New York will be equal global hubs for us.”

20th May 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...